# Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

> **NCT06016855** · PHASE4 · RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 6 (estimated)

## Conditions studied

- Digestive System Neuroendocrine Tumor G1
- Digestive System Neuroendocrine Tumor G2
- Metastatic Digestive System Neuroendocrine Neoplasm
- Metastatic Malignant Neoplasm in the Liver
- Pancreatic Neuroendocrine Tumor G1
- Pancreatic Neuroendocrine Tumor G2

## Interventions

- **PROCEDURE:** Tumor Debulking
- **DRUG:** Lutetium Lu 177 Dotatate
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Copper Cu 64 Dotatate
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06016855
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-31
- **Primary completion:** 2027-05-28
- **Final completion:** 2028-05-28
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016855, "Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06016855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*